Vyvgart® Hytrulo

Understanding Vyvgart® Hytrulo

Vyvgart® Hytrulo is a treatment for generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. This innovative therapy works by blocking the Neonatal Fc Receptor (FcRn), which helps reduce IgG autoantibodies that attack the communication between nerves and muscles. By lowering these harmful autoantibodies, Vyvgart® Hytrulo helps restore muscle strength and improve overall function.

How Vyvgart® Hytrulo Works:

• Targets the FcRn receptor to reduce harmful IgG autoantibodies
• Restores nerve-muscle communication, improving muscle strength
• Reduces symptoms and enhances daily function for individuals with generalized myasthenia gravis (gMG)

FDA Approval:

• Vyvgart® Hytrulo: Approved on June 20, 2023, for anti-AChR antibody-positive generalized myasthenia gravis (gMG)

For more information, please visit the Vyvgart® Hytrulo patient website and speak with your healthcare provider to determine if Vyvgart® Hytrulo is the right treatment option for you.